Replies to post #116 on Alkermes, Inc. (ALKS)

[surf1944]

8:02AM Alkermes provides results from Phase 2 Study of ALKS 33 for Treatment of Binge Eating Disorder; reduction was not significantly different from that observed with placebo (ALKS) 18.70 : Co announces topline results from a phase 2 clinical study of ALKS 33 in the treatment of binge eating disorder. While ALKS 33 demonstrated a significant reduction from baseline in the efficacy endpoint of self-reported weekly binge eating episodes, the reduction was not significantly different from that observed with placebo. Based on these results, the co has determined that future studies in the binge eating indication are less attractive than other potential alternatives and will not pursue further development of ALKS 33 in this area. ALKS 33 remains in development for other central nervous system indications based on the compound's favorable characteristics of once-daily dosing, limited hepatic metabolism and durable pharmacologic activity in modulating brain opioid receptors. ALKS 33 is currently being evaluated as a potential treatment for alcohol dependence and, in combination with buprenorphine as ALKS 5461, for cocaine addiction and treatment-resistant depression.